These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 30290290)

  • 1. Countering clinical inertia in lipid management: Expert workshop summary.
    Zullig LL; Egbuonu-Davis L; Trasy A; Oshotse C; Goldstein KM; Bosworth HB
    Am Heart J; 2018 Dec; 206():24-29. PubMed ID: 30290290
    [No Abstract]   [Full Text] [Related]  

  • 2. Lipids and Cardiovascular Disease: Putting It All Together.
    Pownall HJ; Gotto AM
    Methodist Debakey Cardiovasc J; 2019; 15(1):5-8. PubMed ID: 31049143
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular risk assessment and lipid modification: NICE guideline.
    Duerden M; O'Flynn N; Qureshi N
    Br J Gen Pract; 2015 Jul; 65(636):378-80. PubMed ID: 26120133
    [No Abstract]   [Full Text] [Related]  

  • 4. Guest Editors Henry Pownall and Antonio Gotto Offer Insight and Expertise on the topic of Lipids and Cardiovascular Disease.
    Methodist Debakey Cardiovasc J; 2019; 15(1):4. PubMed ID: 31049142
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of Dyslipidemia in Elderly Patients With Coronary Heart Disease: There Are Miles to Go Before We Sleep.
    Toth PP
    J Am Coll Cardiol; 2015 Oct; 66(17):1873-5. PubMed ID: 26493658
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacological treatment of hypertension and hyperlipidemia in Izhevsk, Russia.
    Cybulsky M; Cook S; Kontsevaya AV; Vasiljev M; Leon DA
    BMC Cardiovasc Disord; 2016 Jun; 16():122. PubMed ID: 27255373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of therapeutic inertia in lipid lowering treatment of primary care patients with high cardiovascular risk].
    de Pablos Vicente MA; Leal Hernández M; Balanza Galindo S; Abellán Alemán J
    Aten Primaria; 2012 Mar; 44(3):e14-5. PubMed ID: 21724299
    [No Abstract]   [Full Text] [Related]  

  • 8. More Nuanced Guidelines for Lipid Lowering to Prevent CVD.
    Shaughnessy AF
    Am Fam Physician; 2016 Jan; 93(1):59. PubMed ID: 26760843
    [No Abstract]   [Full Text] [Related]  

  • 9. Lipid-modifying therapy in the elderly.
    Hamilton-Craig I; Colquhoun D; Kostner K; Woodhouse S; d'Emden M
    Vasc Health Risk Manag; 2015; 11():251-63. PubMed ID: 25999729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ideal Lipid Report: A Need for Consensus.
    Pedro-Botet J; Rodríguez-Padial L; Brotons C; Esteban-Salán M; García-Lerín A; Pintó X; Lekuona I; Ordóñez-Llanos J
    Rev Esp Cardiol (Engl Ed); 2018 Jul; 71(7):512-514. PubMed ID: 29716842
    [No Abstract]   [Full Text] [Related]  

  • 11. Around PediHeart: hyperlipidemia.
    McCaffrey F
    Pediatr Cardiol; 2001; 22(1):52. PubMed ID: 11123128
    [No Abstract]   [Full Text] [Related]  

  • 12. Testing pitfalls and summary of guidance in lipid management.
    Smellie WS
    BMJ; 2006 Jul; 333(7558):83-6. PubMed ID: 16825231
    [No Abstract]   [Full Text] [Related]  

  • 13. Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence.
    Wong MC; Wang HH; Liu KS
    Int J Clin Pract; 2011 Dec; 65(12):1321-2. PubMed ID: 22093540
    [No Abstract]   [Full Text] [Related]  

  • 14. How Much Do Lipid Guidelines Help the Clinician? Reading Between the (Guide)lines.
    Orringer CE
    Methodist Debakey Cardiovasc J; 2019; 15(1):16-22. PubMed ID: 31049145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperlipidemia as a risk factor for cardiovascular disease.
    Nelson RH
    Prim Care; 2013 Mar; 40(1):195-211. PubMed ID: 23402469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is global cardiovascular risk considered in current practice? Treatment and control of hypertension, hyperlipidemia, and diabetes according to patients' risk level.
    Roccatagliata D; Avanzini F; Monesi L; Caimi V; Lauri D; Longoni P; Marchioli R; Tombesi M; Tognoni G; Roncaglioni MC;
    Vasc Health Risk Manag; 2006; 2(4):507-14. PubMed ID: 17323606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk.
    Duntas L; Kolovou G
    Future Cardiol; 2011 Mar; 7(2):137-44. PubMed ID: 21453018
    [No Abstract]   [Full Text] [Related]  

  • 18. Framing cardiovascular disease event risk prediction.
    Stone JA
    Can J Cardiol; 2011; 27(2):171-3. PubMed ID: 21459265
    [No Abstract]   [Full Text] [Related]  

  • 19. Adherence to lipid-lowering agents.
    Ege MR; Yucel O; Acikgoz S
    Int J Clin Pract; 2011 Dec; 65(12):1321. PubMed ID: 22093541
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of Frequency of Lipid Testing With Changes in Lipid-Lowering Therapy.
    Stenehjem K; Herren D; Pulver G; Combs B
    JAMA Intern Med; 2017 Oct; 177(10):1529-1531. PubMed ID: 28846768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.